Poly Medicure Limited (POLYMED)

Healthcare · Healthcare Equipment & Supplies · NSE · Updated 21 July 2026

₹1,695.9 ↓ 18.77% (1Y)

🎯 Key Takeaways

Poly Medicure Limited is in a phase of operational stabilization following a period of growth, with recent financial performance showing consistent profitability but modest revenue expansion. The company maintains strong margins and has recently received a positive credit rating upgrade, signaling improved financial standing.
Revenue grew 1% QoQ to ₹424 in Q3FY25.
⚠️ The ongoing legal challenge against a penalty and alleged stamp duty demand from the Delhi Revenue Department introduces potential regulatory and comp

Market Cap

₹15,193

P/E Ratio

46.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About POLYMED 📊 Interactive Charts

📖 The Story

Poly Medicure Limited is in a phase of operational stabilization following a period of growth, with recent financial performance showing consistent profitability but modest revenue expansion. The company maintains strong margins and has recently received a positive credit rating upgrade, signaling improved financial standing. However, it faces near-term regulatory scrutiny over historical stamp duty matters, which it is contesting without expecting material financial impact.

📰 What's Happening

In the latest regulatory updates, the company received a credit rating upgrade from CRISIL to Positive from Stable on June 26, 2026, with its loan facility increased from Rs.400 crore to Rs.500 crore, reflecting enhanced lender confidence. This follows its June 16, 2026 disclosure of contesting a Rs.1.5 crore penalty and alleged Rs.1.0025 crore stamp duty deficit from the Delhi Revenue Department, which it plans to challenge legally. Additionally, on June 29, 2026, it confirmed that its trading window would close ahead of quarterly results, adhering to SEBI insider trading norms, with the board meeting date to be announced.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	307	321	337	340	378	385	420	424
Operating Profit	92	101	98	107	112	121	141	136
OPM %	27.1%	27.2%	25.0%	26.6%	25.5%	27.0%	27.5%	27.0%
Net Profit	59	63	62	65	68	74	87	85
EPS	₹6.13	₹6.54	₹6.48	₹6.78	₹7.12	₹7.71	₹9.01	₹8.48

The company has demonstrated steady revenue growth, increasing from ₹307 crore in Q4FY23 to ₹424 crore in Q3FY25, with operating margins holding firm around 27% despite macroeconomic pressures. Profitability has improved in line with revenue expansion, as net profit rose from ₹59 crore to ₹85 crore over the same period, supporting EPS growth from ₹6.13 to ₹8.48. This consistent performance suggests effective cost management and operational efficiency, likely underpinned by strategic investments or scaling initiatives referenced in management commentary.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the latest available filings, but the positive credit rating upgrade and expanded credit facility suggest confidence in future cash flow generation and financial flexibility. The company continues to focus on regulatory compliance and operational excellence, as evidenced by its adherence to SEBI norms and proactive legal response to government orders. No official projections or growth targets were disclosed in the recent announcements.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Equipment & Supplies

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Poly Medicure Limited	15,193	46.4	—	—	—
Fischer Medical Ventures Limited	2,261	59.0	—	—	—
Laxmi Dental Limited	1,105	57.2	—	—	—
Tarsons Products Limited	1,101	36.9	—	—	—
Fabtech Technologies Limited	681	—	—	—	—
Nureca Limited	260	-47.3	—	—	—

🔗 Peer Stock Analyses

FISCHER LAXMIDENTL TARSONS FABTECH NURECA

⚠️ Risk Factors

1. The ongoing legal challenge against a penalty and alleged stamp duty demand from the Delhi Revenue Department introduces potential regulatory and compliance risk, despite management’s assertion of minimal financial impact. 2. The company’s high P/E ratio of 46.4 relative to sector peers may reflect elevated valuation expectations, making the stock vulnerable to earnings volatility. 3. The absence of formal forward guidance limits predictability around future performance, increasing investor uncertainty. 4. Exposure to regulatory scrutiny in key operational jurisdictions could impact reputation or require increased compliance costs.

📋 Recent Filings

🧠 Analyst's Read

Poly Medicure is navigating a stable but unremarkable growth phase, supported by consistent margins and improving profitability, though revenue expansion remains incremental. The company’s financial resilience is reinforced by its upgraded credit rating, but near-term focus appears centered on resolving regulatory matters rather than pursuing aggressive expansion. Investors should monitor upcoming quarterly results for signs of sustained momentum and any commentary on demand trends or margin outlook, while remaining cautious of regulatory overhangs.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on POLYMED

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when POLYMED files new disclosures

Track POLYMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track POLYMED — Free

Free account · 2 AI queries/day